The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

Glioblastomas (GBMs) are among the most malignant of all human tumors and have poor prognosis. The current standard of care (SOC) includes maximal surgical tumor resection followed by adjuvant temozolomide (TMZ) and concomitant radiotherapy (RT). However, even with this treatment, the 5-year surviva...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Shi, Fei, Zhang, Jinying, Liu, Hongyu, Wu, Liangliang, Jiang, Hongyu, Wu, Qiyan, Liu, Tianyi, Lou, Meiqing, Wu, Hao
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5787502/
https://ncbi.nlm.nih.gov/pubmed/29416647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23091
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi